IGI Logo

Piramal Pharma is currently trading at Rs. 138.45, up by 0.30 points or 0.22% from its previous closing of Rs. 138.15 on the BSE.

The scrip opened at Rs. 138.20 and has touched a high and low of Rs. 140.15 and Rs. 136.60 respectively. So far 58908 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 145.80 on 05-Jan-2024 and a 52 week low of Rs. 61.68 on 28-Mar-2023.

Last one week high and low of the scrip stood at Rs. 145.00 and Rs. 136.40 respectively. The current market cap of the company is Rs. 18388.98 crore.

The promoters holding in the company stood at 35.02%, while Institutions and Non-Institutions held 40.39% and 24.59% respectively.

Piramal Pharma’s division -- Piramal Critical Care (PCC) has launched new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the U.S. The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio.

Zinc Sulfate is a trace element indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. This intravenous nutritional injection is available in three strengths: 30mg/10mL (3mg/mL), 25mg/5mL (5mg/mL), and the new 10mg/10mL (1mg/mL) concentration. The 1 mg/mL concentration is recommended for use in pediatric patients, particularly those weighing less than 26 pounds.

The launch of Zinc Sulfate for Injection, USP 10mg/10ml is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2023, Piramal Critical Care also announced launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further complement their wide portfolio of critical care products.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.